Pre-reimbursement: early assessment for coverage decisions.

Vorab-Erstattung: Frühbewertungen für Erstattungsentscheidungen.

Journal

Wiener medizinische Wochenschrift (1946)
ISSN: 1563-258X
Titre abrégé: Wien Med Wochenschr
Pays: Austria
ID NLM: 8708475

Informations de publication

Date de publication:
Sep 2019
Historique:
received: 06 11 2018
accepted: 15 01 2019
pubmed: 7 2 2019
medline: 21 9 2019
entrez: 7 2 2019
Statut: ppublish

Résumé

In the past decade, the Ludwig Boltzmann Institute for Health Technology Assessment (LBI-HTA) has introduced two programs: "Horizon Scanning in Oncology" (HSO) and extra medical services ("MELs"), which are to facilitate coverage decisions based on early assessments. This article aims to outline the general process and methods within these two programs. A narrative-descriptive synthesis of the literature was performed to outline the general and LBI-HTA-specific processes and methods of early assessments. In total, 79 HSO assessments (2009-2018) and 95 MELs (2008-2018) have been conducted by the LBI-HTA. Recently, additional methods that contribute to European applicability have been introduced into these programs. Overall, pre-coverage decisions based on early assessment reports are dependent on the existing evidence. However, the organisation of the health care system and the cross-linking between decision-makers and HTA institutions can have an impact.

Sections du résumé

BACKGROUND BACKGROUND
In the past decade, the Ludwig Boltzmann Institute for Health Technology Assessment (LBI-HTA) has introduced two programs: "Horizon Scanning in Oncology" (HSO) and extra medical services ("MELs"), which are to facilitate coverage decisions based on early assessments. This article aims to outline the general process and methods within these two programs.
METHODS METHODS
A narrative-descriptive synthesis of the literature was performed to outline the general and LBI-HTA-specific processes and methods of early assessments.
RESULTS RESULTS
In total, 79 HSO assessments (2009-2018) and 95 MELs (2008-2018) have been conducted by the LBI-HTA. Recently, additional methods that contribute to European applicability have been introduced into these programs.
CONCLUSIONS CONCLUSIONS
Overall, pre-coverage decisions based on early assessment reports are dependent on the existing evidence. However, the organisation of the health care system and the cross-linking between decision-makers and HTA institutions can have an impact.

Identifiants

pubmed: 30725442
doi: 10.1007/s10354-019-0683-1
pii: 10.1007/s10354-019-0683-1
pmc: PMC6713676
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

254-262

Références

PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
J Clin Epidemiol. 2011 Apr;64(4):383-94
pubmed: 21195583
Health Econ Policy Law. 2012 Jan;7(1):25-45
pubmed: 22221927
Int J Technol Assess Health Care. 2012 Apr;28(2):171-9
pubmed: 22559761
Int J Technol Assess Health Care. 2012 Jul;28(3):301-7
pubmed: 22980708
BMC Cardiovasc Disord. 2014 Nov 04;14:154
pubmed: 25366498
Int J Technol Assess Health Care. 2014 Nov;30(5):488-96
pubmed: 25747557
Int J Technol Assess Health Care. 2014 Nov;30(5):497-503
pubmed: 25747558
Ann Oncol. 2015 Aug;26(8):1547-73
pubmed: 26026162
Eur J Intern Med. 2015 Oct;26(8):572-84
pubmed: 26342723
Z Evid Fortbild Qual Gesundhwes. 2015;109(4-5):291-9
pubmed: 26354129
Health Policy. 2015 Nov;119(11):1424-32
pubmed: 26362086
Int J Technol Assess Health Care. 2016 Jan;32(1-2):54-60
pubmed: 26956146
J Public Health (Oxf). 2017 Jun 1;39(2):248-253
pubmed: 27160863
Health Policy. 2016 Aug;120(8):903-12
pubmed: 27344197
JAMA Intern Med. 2017 Feb 1;177(2):276-277
pubmed: 27898978
Front Pharmacol. 2017 Jan 24;8:14
pubmed: 28174538
Value Health. 2017 Feb;20(2):244-250
pubmed: 28237203
Eur J Cancer. 2017 Sep;82:66-71
pubmed: 28648700
ESMO Open. 2017 Jan 31;1(6):e000125
pubmed: 28848662
Front Pharmacol. 2017 Aug 23;8:497
pubmed: 28878667
Ann Oncol. 2017 Oct 1;28(10):2340-2366
pubmed: 28945867
Front Pharmacol. 2017 Oct 05;8:674
pubmed: 29056910
Int J Technol Assess Health Care. 2018 Jan;34(1):18-26
pubmed: 29258630
Pain Physician. 2018 Sep;21(5):E467-E476
pubmed: 30282388

Auteurs

Nicole Grössmann (N)

Ludwig Boltzmann Institute for Health Technology Assessment, Garnisongasse 7/20, 1090, Vienna, Austria. Nicole.Groessmann@hta.lbg.ac.at.
Department of Health Economics, Center for Public Health, Medical University of Vienna, Vienna, Austria. Nicole.Groessmann@hta.lbg.ac.at.

Sarah Wolf (S)

Ludwig Boltzmann Institute for Health Technology Assessment, Garnisongasse 7/20, 1090, Vienna, Austria.

Katharina Rosian (K)

Ludwig Boltzmann Institute for Health Technology Assessment, Garnisongasse 7/20, 1090, Vienna, Austria.

Claudia Wild (C)

Ludwig Boltzmann Institute for Health Technology Assessment, Garnisongasse 7/20, 1090, Vienna, Austria.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH